Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01670877
Recruitment Status : Completed
First Posted : August 22, 2012
Last Update Posted : April 22, 2021
Puma Biotechnology, Inc.
United States Department of Defense
Information provided by (Responsible Party):
Washington University School of Medicine